Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04300244 |
| Title | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU) |
| Acronym | NIPU |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Aslaug Helland |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | SWE | NOR | ESP | DNK | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Western Australia | Perth | Australia | Details | |||
| Aalborg University Hospital | Aalborg | Denmark | Details | |||
| Copenhagen University Hospital | Copenhagen | Denmark | Details | |||
| Oslo University Hospital | Oslo | Norway | Details | |||
| Vall d'Hebron institute of oncology | Barcelona | Spain | Details | |||
| University Hospital of Skåne | Lund | Sweden | Details | |||
| Karolinska | Stockholm | Sweden | Details |